ERBB2 and breast cancer: Noteworthy, in this context, combinations of targeted agents, including the association of the HER2 blockade with endocrine therapy, as well as CDK 4 and 6 inhibitors, show some promise, since CDK 4 and 6 activity are typically dysregulated and overactive in BC [18].